GlaxoSmithKline Intellectual Property Limited
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
2
Ending by 2030
Jun 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 27, 2027The maintenance fee for Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Disease (US 9,168,286) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.
- 1 fee due Aug 11, 2027The maintenance fee for Anti-Blys antibody formulations and methods of treatment using them (US 10,556,009) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,211,649 | Methods of Diagnosing and Prognosing Hodgkin's Lymphoma In force · High confidence | In force | High confidence | |
| US 9,168,286 | Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Disease In force · High confidence | In force | High confidence | |
| US 10,556,009 | Anti-Blys antibody formulations and methods of treatment using them In force · USPTO record | In force | USPTO record | |
| US 11,179,463 | BLyS antibody formulation In force · USPTO record | In force | USPTO record | |
| US 12,296,007 | High concentration anti-blys pharmaceutical formulations In force · USPTO record | In force | USPTO record | |
| US 11,180,569 | Methods of Treating Autoimmune Disorders Using a Combination of ANTI-CD20 and Anti-Blys Antibodies In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 3 patents in force now held by others · 5 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 1 no status recorded